HC Wainwright Reiterates “Buy” Rating for Karyopharm Therapeutics (NASDAQ:KPTI)

HC Wainwright reaffirmed their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research note released on Wednesday morning, Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.08) EPS, FY2025 earnings at ($0.96) EPS and FY2026 earnings at ($0.43) EPS.

Several other equities research analysts have also issued reports on KPTI. Robert W. Baird dropped their target price on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an outperform rating for the company in a research report on Wednesday. Royal Bank of Canada restated an outperform rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $4.80.

Karyopharm Therapeutics Stock Performance

Shares of Karyopharm Therapeutics stock traded down $0.03 during trading hours on Wednesday, reaching $0.81. The company’s stock had a trading volume of 329,845 shares, compared to its average volume of 1,487,917. Karyopharm Therapeutics has a one year low of $0.62 and a one year high of $1.95. The company has a market capitalization of $100.94 million, a P/E ratio of -0.64 and a beta of 0.21. The stock’s fifty day simple moving average is $0.93 and its two-hundred day simple moving average is $1.12.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The company had revenue of $33.13 million for the quarter, compared to analysts’ expectations of $35.02 million. As a group, research analysts forecast that Karyopharm Therapeutics will post -1.16 earnings per share for the current year.

Insider Buying and Selling at Karyopharm Therapeutics

In other Karyopharm Therapeutics news, Director Deepika Pakianathan sold 204,394 shares of the business’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $0.95, for a total transaction of $194,174.30. Following the transaction, the director now owns 14,697 shares of the company’s stock, valued at $13,962.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders sold 1,279,081 shares of company stock valued at $1,237,898. 4.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Los Angeles Capital Management LLC acquired a new stake in Karyopharm Therapeutics in the fourth quarter valued at $339,000. Panagora Asset Management Inc. purchased a new stake in shares of Karyopharm Therapeutics in the fourth quarter valued at $197,000. Acadian Asset Management LLC purchased a new position in Karyopharm Therapeutics during the second quarter worth about $167,000. Monashee Investment Management LLC purchased a new position in Karyopharm Therapeutics during the fourth quarter worth about $115,000. Finally, BNP Paribas Financial Markets increased its stake in Karyopharm Therapeutics by 6.5% during the fourth quarter. BNP Paribas Financial Markets now owns 1,769,184 shares of the company’s stock worth $1,530,000 after acquiring an additional 108,286 shares during the last quarter. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).